期刊文献+

伊马替尼治疗慢性粒细胞白血病急变期的疗效观察 被引量:5

下载PDF
导出
摘要 目的探讨伊马替尼治疗慢性粒细胞白血病急变期的疗效。方法选择2009年01月至2011年04月期间诊治的慢性粒细胞白血病急变期患者9例,应用伊马替尼进行治疗,观察其血液学缓解率、细胞遗传学缓解率和不良反应。结果 9例慢性粒细胞白血病急变期患者中,4例患者达到完全缓解(4/9,44.44%),3例患者部分缓解(3/9,33.33%),总体有效率达77.78%(7/9)。l例患者自行停药后,病情出现恶化,最终死亡,1例患者自动出院。9例慢性粒细胞白血病急变期患者中,4例患者复查Ph染色体时,转为阴性,Ph染色体转阴率为44.44%。9例慢性粒细胞白血病急变期患者接受伊马替尼治疗后,白细胞、血红蛋白和血小板都出现减少,但是减少程度并不严重。9例慢性粒细胞白血病急变期患者中,2例患者出现眼眶以及下肢水肿,1例患者出现全身肌肉或者关节酸痛,没有患者出现明显肝肾功能异常等严重不良反应。结论伊马替尼治疗的慢性粒细胞白血病急变期患者,疗效较好,值得临床广泛推广。
作者 徐玉秀 孙慧
出处 《当代医学》 2011年第28期142-143,共2页 Contemporary Medicine
  • 相关文献

参考文献5

二级参考文献67

  • 1盛立霞,邱国强,谢晓宝,顾伟英,王志林,吴浩清.两种白血病细胞抗原负载DC的体外诱导特异性CTL应答的比较[J].细胞与分子免疫学杂志,2005,21(2):205-209. 被引量:12
  • 2艾丽梅,张欣,谭威.MA和DA方案治疗成人急性髓细胞性白血病疗效观察[J].中国医药导报,2007,4(01X):32-33. 被引量:9
  • 3翁开枝,谢晓宝,邱国强,吴浩清,顾伟英.GM-CSF+IFN-α诱导CML患者骨髓单个核细胞分化的树突细胞的免疫应答[J].细胞与分子免疫学杂志,2007,23(3):229-231. 被引量:3
  • 4谢风祥(综述),毛海婷(审校).干扰素在肿瘤细胞凋亡信号传导通路中的作用及影响[J].国际肿瘤学杂志,2007,34(6):404-406. 被引量:2
  • 5Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European leukemia Net. Blood, 2006 , 108 (6) : 1809-1820.
  • 6Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells:Implications for drug resistance. Blood,2004, 104(12) :3739-3745.
  • 7Crossman LC, Druker BJ, Deininger MW, et al. hOCT 1 and resistance to imatinib. Blood,2005 ; 106(3):1133-1134.
  • 8Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to Imatinib in chronic myeloid leukemia. Clin Pharmacol Ther,2008;83(2) :258-264.
  • 9White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to Imatinib have low OCT-1 activity: higher doses of Imatinih may overcome the negative Impact of low OCT-1 activity. Blood, 2007 , 110(2) : 4064-4072.
  • 10Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia[ J]. Cancer lett, 2007, 249(2) : 121 - 127.

共引文献30

同被引文献47

  • 1江倩,陈珊珊,江滨,江浩,陆颖,陆道培.伊马替尼治疗慢性粒细胞白血病加速期疗效评价[J].中华血液学杂志,2004,25(6):333-336. 被引量:15
  • 2魏辉,王建祥.伊马替尼治疗慢性粒细胞白血病的疗效与毒副反应[J].中国实用内科杂志,2007,27(20):1582-1586. 被引量:1
  • 3Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy [ J ]. J Pharmacol Exp Ther,2005,315 ( 3 ) :971-979.
  • 4Breccia-M, Efficace F, Alimena GI Imatinib treatment in chronic myelogenous leukemia:what have we learned so far? [ J 3. Cancer Lett,2011,300(2) :115-121.
  • 5Frolov A, Chahwan S, Ochs M, et al. Response markers and them olecularm echanisms of action of Gleevec in gastrointestinal stromal tumors [ J ]. Mol Cancer Ther,2003,2 ( 8 ) :699-709.
  • 6Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma [ J ]. J Hepatol,2004,41 ( 5 ) :864-880.
  • 7江倩,陈珊珊,江滨,江浩,丘镜莹,刘艳荣,张燕,秦亚溱,陆颖,黄晓军,陆道培.伊马替尼治疗124例慢性粒细胞白血病加速期和急变期疗效追踪[J].中华血液学杂志,2007,28(11):721-726. 被引量:9
  • 8江继发,金凤祥,肖明敏,程文燕.甲磺酸伊马替尼治疗慢性粒细胞性白血病的疗效观察[J].实用诊断与治疗杂志,2007,21(12):942-943. 被引量:8
  • 9Cheng Zhiyong,Liang Wentong,Yang Xiaoyang,Pan Ling.PTEN’s regulation of VEGF and VEGFR1 expression and its clinical significance in myeloid leukemia[J]. Medical Oncology . 2012 (2)
  • 10Aiko Suminoe,Akinobu Matsuzaki,Hiroyoshi Hattori,Yuhki Koga,Eiichi Ishii,Toshiro Hara.Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement[J]. Leukemia Research . 2007 (10)

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部